Edit

Impel NeuroPharma

http://impelnp.com/

Last activity: 19.01.2022

Active

Categories: BusinessDeliveryDrugHardwareIndustryLifeLivingSoftwareTechnologyTime

Veeva Systems is a leader in cloud-based software for the global life sciences industry. Our customers achieve the fastest time to value through the deployment of fully functional business applications that are flexible to change, simple to deploy, inexpensive to operate, and provide a superior user experience.

Likes

3.14K

Followers

6.01K

Mentions

Location: United States, Washington, Seattle

Employees: 51-200

Phone: (925) 452-6500

Total raised: $183.5M

Founded date: 2008

Twitter

Investors 3

Date	Name	Website
-	5AM Ventur...	5amventure...
-	Vivo Capit...	vivocapita...
-	Kohlberg K...	kkr.com

Funding Rounds 3

Date	Series	Amount	Investors
23.04.2021	IPO	$80M	-
06.12.2018	Series D	$67.5M	-
06.12.2016	Series C	$36M	5AM Ventur...

Mentions in press and media 26

Date	Title	Description
19.01.2022	Impel NeuroPharma Provides Updates on Trudhesa Launch and Recent Business Highlights	SEATTLE - Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system,...
18.01.2022	Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights	Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s Guidance Range Achieved Broad and Favorable Trudhesa™ Payer Coverage with Signed Agree...
18.01.2022	Impel NeuroPharma : Provides Updates on TrudhesaTM Launch and Recent Business Highlights - Form 8-K	Impel NeuroPharma Provides Updates on TrudhesaTM Launch and Recent Business Highlights Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company's...
15.11.2021	Impel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update	Launched Trudhesa™ (dihydroergotamine mesylate) Nasal Spray (0.725 mg per spray) for the Acute Treatment of Migraine with and without Aura in Adults Mobilized 60-Person Salesforce with a Targeted Focus on High-Prescribing Neurologists, Head...
15.11.2021	Impel NeuroPharma : Announces THIRD Quarter 2021 Financial Results and Provides CORPORATE Update - Form 8-K	Impel NeuroPharma Announces THIRD Quarter 2021 Financial Results and Provides CORPORATE Update Launched Trudhesa™ (dihydroergotamine mesylate) Nasal Spray (0.725 mg per spray) for the Acute Treatment of Migraine with and without Aura in Adu...
29.09.2021	Impel NeuroPharma : Announces Trudhesa (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of Migraine	SEATTLE - Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervou...
28.09.2021	Impel NeuroPharma : Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of Migraine	Trudhesa is the First and Only Therapeutic to Use POD® Technology to Deliver Dihydroergotamine Mesylate (DHE)—a Proven, Well-Established Therapeutic—to the Vascular-Rich Upper Nasal Space Trudhesa is Available Through Trudhesa Direct™, Whic...
10.09.2021	Impel NeuroPharma : Announces Pricing of $45.0 Million Public Offering	SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an i...
16.08.2021	Impel NeuroPharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update	TRUDHESA™ New Drug Application (NDA) Under Review by U.S. Food & Drug Administration (FDA) with PDUFA Target Action Date of September 6, 2021 Preparations On Track for Potential TRUDHESA Launch in the Fourth Quarter of 2021 Increased Ca...
16.08.2021	Impel NeuroPharma : Increased Cash Position and Extended Runway through 2022 Following $50 Million Debt Facility Agreement with Oxford Finance LLC and Silicon Valley Bank (Form 8-K)	Increased Cash Position and Extended Runway through 2022 Following $50 Million Debt Facility Agreement with Oxford Finance LLC and Silicon Valley Bank Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, August 16, 2021 - I...
09.08.2021	Impel NeuroPharma : Announces Publication of Pivotal Phase 3, Open-Label Stop 301 Study of INP104 (TRUDHESA™) for Treatment of Acute Migraine in the Journal Headache	Study Shows TRUDHESA™ Was Well Tolerated and Delivered Rapid, Consistent Symptom Relief Exploratory Patient-Reported Outcomes Data Indicated More Than One Third of Patients Experienced Pain Freedom and Two Thirds Had Pain Relief Two Hours F...
26.04.2021	Impel Neuropharma raises $80M in IPO	Drugmaker Impel Neuropharma has raised $80 million after selling 5.33 million shares at $15 apiece in its Nasdaq IPO. The stock closed its first day of trading unchanged from that price, valuing the company at about $291 million based on th...
23.04.2021	Impel Neuropharma raises $80M in Washington state’s first IPO of 2021	Impel CEO Adrian Adams. (Impel Photo) The news: Seattle-based biotech company Impel NeuroPharma raised $80 million in its initial public offering and will begin trading on the NASDAQ Friday under the ticker IMPL. It is the first Washington ...
23.04.2021	Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering	-
22.04.2021	Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering	-
05.04.2021	Seattle biotech firm Impel NeuroPharma files for $75M IPO	Impel CEO Adrian Adams. (Impel Photo) Seattle-based biotech company Impel NeuroPharma is set to go public. The company, which develops drugs for central nervous system disorders such as migraines and Parkinson’s, submitted paperwork on Frid...
07.03.2021	Satsuma Pharma rounds up $80M to give its migraine treatment another shot	Later this month, San Francisco-based Satsuma plans to start a Phase 1 study to evaluate three different dose strengths of its migraine treatment. By mid-year, the company expects to take the selected dose into a new Phase 3 study. Satsusma...
07.12.2018	Impel NeuroPharma Closes $67.5M in Series D Financing	Impel NeuroPharma, a Seattle, WA-based biotechnology company focused on developing therapies for the treatment of central nervous system (“CNS”) disorders with unmet medical needs, completed a $67.5m Series D financing. The round was co-led...
07.12.2018	Term Sheet — Friday, December 7	TIK-TOK Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop Never heard of ByteDance? With a valuation of $75 billion (!), it’s the world’s most valuable startup. (I know, hard to be...
06.12.2018	Impel NeuroPharma Closes $67.5 Million Series D Financing	Crossover Financing to Advance Clinical Development of Central Nervous System Assets in Migraine, Parkinson's Disease and Acute Agitation SEATTLE, Dec. 6, 2018 /PRNewswire/ -- Impel NeuroPharma ("Impel" or the "Company"...
06.12.2018	Impel NeuroPharma Closes $67.5 Million Series D Financing	-
06.12.2016	NeuroPharma Raises $36M Series C from 5AM Ventures	SEATTLE--(BUSINESS WIRE)--Impel NeuroPharma, Inc., a Seattle-based clinical stage biotechnology company developing first-in-class intranasal drug treatments for central nervous (CNS) disorders, today announced that it has closed a Series C ...
03.12.2016	Impel NeuroPharma raises $36M for drug delivery platform that bypasses blood-brain barrier	Impel NeuroPharma co-founder and CEO John Hoekman. (Impel NeuroPharma Photo) Impel NeuroPharma, a Seattle-based biotechnology and pharmaceutical company, announced a $36 million Series C round to develop neurological drugs and an accompanyi...
02.12.2016	Impel NeuroPharma Raises $36M in Funding	Impel NeuroPharma, Inc., a Seattle, WA-based clinical stage biotechnology company developing intranasal drug treatments for central nervous (CNS) disorders, closed a Series C funding round in an amount up to $36M. Backers included venBIO, 5...
16.10.2013	Veeva Systems’ Life Science Cloud IPO Is A Hit, Raising $217M And Closing Up 85%	Veeva Systems, an enterprise cloud provider for life sciences companies like Pfizer, IPO’d on the NYSE this morning, raising around $217 million by upping its share price $20. Veeva saw a pop of 83.5% in initial trading after starting at a ...
-	Satsuma Pharma rounds up $80M to give its migraine treatment another shot	Satsuma Pharmaceuticals fell short in a Phase 3 study testing its treatment for migraine headaches, a clinical trial failure widely expected to spark the end of the program and the company. Instead, Satsuma now has a new plan that has persu...

Impel NeuroPharma

Investors 3

Funding Rounds 3

Mentions in press and media 26

Reviews 0